1. Home
  2. INFU vs SABS Comparison

INFU vs SABS Comparison

Compare INFU & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo InfuSystems Holdings Inc.

INFU

InfuSystems Holdings Inc.

HOLD

Current Price

$9.31

Market Cap

211.6M

Sector

Health Care

ML Signal

HOLD

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

HOLD

Current Price

$3.99

Market Cap

181.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INFU
SABS
Founded
2005
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
211.6M
181.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
INFU
SABS
Price
$9.31
$3.99
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$14.50
$9.00
AVG Volume (30 Days)
123.5K
253.6K
Earning Date
11-04-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
271.43
N/A
EPS
0.26
N/A
Revenue
$141,054,000.00
$114,698.00
Revenue This Year
$8.84
N/A
Revenue Next Year
$3.67
N/A
P/E Ratio
$35.63
N/A
Revenue Growth
6.23
N/A
52 Week Low
$4.61
$1.00
52 Week High
$11.04
$6.60

Technical Indicators

Market Signals
Indicator
INFU
SABS
Relative Strength Index (RSI) 48.42 58.29
Support Level $8.98 $3.54
Resistance Level $9.31 $4.04
Average True Range (ATR) 0.32 0.30
MACD 0.04 -0.03
Stochastic Oscillator 63.27 72.47

Price Performance

Historical Comparison
INFU
SABS

About INFU InfuSystems Holdings Inc.

InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-reportable segment. The first is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second, Device Solutions, supports the Patient Services platform and leverages service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Majority from Patient.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Share on Social Networks: